Cargando…
Induction of human pancreatic beta cell replication by inhibitors of dual specificity tyrosine regulated kinase
Types 1 and 2 diabetes affect some 380 million people worldwide. Both result ultimately from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with peak beta cell labeling indices ac...
Autores principales: | Wang, Peng, Alvarez-Perez, Juan-Carlos, Felsenfeld, Dan P., Liu, Hongtao, Sivendran, Sharmila, Bender, Aaron, Kumar, Anil, Sanchez, Roberto, Scott, Donald K., Garcia-Ocaña, Adolfo, Stewart, Andrew F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690535/ https://www.ncbi.nlm.nih.gov/pubmed/25751815 http://dx.doi.org/10.1038/nm.3820 |
Ejemplares similares
-
OR12-02 NRF2 Is Essential For Expanding Pancreatic Beta-Cell Mass During Pregnancy
por: Baumel-Alterzon, Sharon, et al.
Publicado: (2023) -
Large parental differences in chromatin organization in pancreatic beta cell line explaining diabetes susceptibility effects
por: Jian, Xing, et al.
Publicado: (2021) -
Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008) -
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
por: Gong, Juejun, et al.
Publicado: (2021) -
Glucocorticoids and checkpoint tyrosine kinase inhibitors stimulate rat pancreatic beta cell proliferation differentially
por: Akbib, Sarah, et al.
Publicado: (2019)